Teva to Present at the Barclays Capital 2011 Global Healthcare Conference

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Barclays Capital 2011 Global Healthcare Conference with Jon Congleton, SVP & General Manager, Teva Neuroscience, presenting on Wednesday, March 16, 2011 in Miami.

What:

  Teva Presentation at the Barclays Capital 2011 Global Healthcare Conference
 

Who:

Jon Congleton, SVP & General Manager, Teva Neuroscience
 

When:

Wednesday, March 16, 2011 at 4:15pm ET
 

Where:

www.tevapharm.com/financial/ or

http://cc.talkpoint.com/barc002/031511a_rb/?entity=46_MGU1R3W

 

How:

Live over the Internet – log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.
 

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.



CONTACT:

IR:
Teva Pharmaceutical Industries Ltd.
Elana Holzman, 972 (3) 926-7554
or
Teva North America
Kevin C. Mannix, 215-591-8912
or
PR:
Teva Pharmaceutical Industries Ltd.
Yossi Koren, 972 (3) 926-7687
or
Teva North America
Denise Bradley, 215-591-8974

KEYWORDS:   United States  North America  Florida  New York

INDUSTRY KEYWORDS:   Health  Pharmaceutical  General Health

MEDIA:

Suggested Articles

Sun Pharma has recalled one lot of its generic metformin after finding high levels of the probable carcinogen NDMA in tested lots.

Six months after WHO declared a pandemic, the list of drugs proven to work against the virus remains short. Now, Fujifilm has added its drug Avigan.

ICER said that Vertex's triplet CF therapy Trikafta would only be cost effective if the price were dropped from $311,000 to no more than $85,500.